期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

原发性血小板增多症诊断与治疗中国专家共识（2016年版） 被引量：70

Chinese expert consensus on the diagnosis and treatment of essential thrombcythaemia （2016）
原文传递
导出
摘要 为了进一步规范我国血液科医师对原发性血小板增多症（ET）患者的临床诊治，由中华医学会血液学分会白血病淋巴瘤学组牵头，在广泛征求国内专家意见的基础上，最终达成了ET的诊断程序、实验室检查、诊断标准和治疗原则等方面的共识。
机构地区 中华医学会血液学分会白血病淋巴瘤学组
出处 《中华血液学杂志》 CAS CSCD 北大核心 2016年第10期833-836,共4页 Chinese Journal of Hematology
关键词 原发性血小板增多症 专家意见 诊断程序 治疗原则 中国 中华医学会 实验室检查 临床诊治
分类号 R558.3 [医药卫生—血液循环系统疾病]
  • 相关文献

参考文献20

  • 1徐俊卿,徐泽锋,王静雅,李冰,孙秀娟,秦铁军,张悦,张宏丽,方力维,潘丽娟,胡耐博,曲士强,肖志坚.615例Ph染色体／BCR—ABL融合基因阴性骨髓增殖性肿瘤患者的症状负荷评估[J].中华血液学杂志,2016,37(1):26-29. 被引量：16
  • 2Harrison CN, Bareford D, Butt N, et al. Guideline for investiga- tion and management of adults and children presenting with a thrombocytosis [J]. Br J Haematol, 2010, 149 (3):352-375. doi: 10.1111/j.1365-2141.2010.08122.x.
  • 3Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet [J]. J Clin Oncol, 2011, 29 (6):761-770. doi: 10.1200/ JCO.2010.31.8436.
  • 4Harrison CN, Butt N, Campbell P, et al. Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia [J]. Br J Haematol, 2014, 167 (3): 421-423. doi: 10.1111/bjh.12986.
  • 5Vannucchi AM, Barbui T, Cervantes F, et al. Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J]. Ann Oncol, 2015, 26 Suppl 5:v85-99. doi: 10.1093/annonc/mdv203.
  • 6Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood, 2016, 127 (20):2391-2405. doi: 10.1182/blood-2016-03-643544.
  • 7Besses C, Hemfindez-Boluda JC, Prez Encinas M, et al. Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method[J]. Ann Hematol, 2016, 95 (5):719-732. doi: 10.1007/ s00277-016-2614-1.
  • 8Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment[J]. Leukemia, 2008, 22(2):437-438. doi:10.1038/sj. leu.2404914.
  • 9Kvasnicka HM, Thiele J. Prodromal myeloproliferative neoplasms: the 2008 WHO classification [J]. Am J Hematol, 2010, 85( 1 ):62-69. doi: 10.1002/ajh.21543.
  • 10Barbui T, Thiele J, Vannucchi AM, et al. Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primarymyelofibrosis versus essential thrombocythemia [J]. Leukemia, 2013, 27( 10):1953-1958. doi: 10.1038/leu.2013.74.

二级参考文献29

  • 1Mesa RA, Verstovsek S, Cervantes F, et al. Primary myelofibro- sis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT) IJ]. Leuk Res, 2007, 31 (6):737- 740.
  • 2Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs ~ J ]. J Clin Oncol, 2012, 30(33):4098-4103.
  • 3Thiele J, Kvasnicka HM, Facchetti F, et al. European consensus on grading bone marrow fibrosis and assessment of cellularity [J]. Haematologica, 2005, 90(8):1128-1132.
  • 4Tefferi A, Vardiman JW. Classification and diagnosis of myelo- proliferative neoplasms: the 2008 World Health Organization cri- teria and point-of-care diagnostic algorithms [J]. Leukemia, 2008, 22 ( 1 ): 14-22.
  • 5Tefferi A, Thiele J, Vannuechi AM, et al. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diag- nostic eriteria for myeloproliferative neoplasms [Jl. Leukemia, 2014, 28(7):1407-1413.
  • 6Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the Inter- national Working Group for Myelofibrosis Research and Treat- ment[J]. Blood, 2009, 113( 13): 2895-2901.
  • 7Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) IJ~. Blood, 2010, 115(9):1703-1708.
  • 8Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status I J]. J Clin Oncol, 2011, 29(4):392-397.
  • 9Xu Z, Gale RP, Zhang Y, et al. Unique features of primary myelofibrosis in Chinese I J ]. Blood, 2012, 119 ( 11 ) :2469-2473.
  • 10Barosi G, Ambrosetti A, Finelli C, et al. The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia~J~. Br J Haematol, 1999, 104(4):730-737.

共引文献45

同被引文献367

引证文献70

二级引证文献106

中华血液学杂志
2016年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部